United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report & Forecast 2021-2027

United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Pulmonary Arterial Hypertension (PAH) Drugs Overall Market Size
2.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2027
2.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales: 2016-2027
3 Company Landscape
3.1 Top Pulmonary Arterial Hypertension (PAH) Drugs Players in United States Market
3.2 Top United States Pulmonary Arterial Hypertension (PAH) Drugs Companies Ranked by Revenue
3.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies
3.4 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies
3.5 United States Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Pulmonary Arterial Hypertension (PAH) Drugs Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Players in United States Market
3.8.1 List of Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies in United States
3.8.2 List of Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size Markets, 2021 & 2027
4.1.2 Inhalation
4.1.3 Injectables
4.1.4 Oral Administration
4.2 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
4.2.1 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2016-2021
4.2.2 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2022-2027
4.2.3 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2016-2027
4.3 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
4.3.1 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2016-2021
4.3.2 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2022-2027
4.3.3 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2016-2027
4.4 By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2021 & 2027
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
5.2.1 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2016-2021
5.2.2 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2022-2027
5.2.3 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2016-2027
5.3 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
5.3.1 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2016-2021
5.3.2 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2022-2027
5.3.3 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2016-2027
5.4 By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Overview
6.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.1.5 Pfizer Recent Developments
6.2 Glaxosmithkline
6.2.1 Glaxosmithkline Corporation Information
6.2.2 Glaxosmithkline Overview
6.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.2.5 Glaxosmithkline Recent Developments
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Overview
6.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.3.5 Novartis Recent Developments
6.4 United Therapeutics
6.4.1 United Therapeutics Corporation Information
6.4.2 United Therapeutics Overview
6.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.4.5 United Therapeutics Recent Developments
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Overview
6.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.5.5 AstraZeneca Recent Developments
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Overview
6.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.6.5 Merck Recent Developments
6.7 Bayer Healthcare
6.7.1 Bayer Healthcare Corporation Information
6.7.2 Bayer Healthcare Overview
6.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.7.5 Bayer Healthcare Recent Developments
6.8 Actelion Pharmaceuticals
6.8.1 Actelion Pharmaceuticals Corporation Information
6.8.2 Actelion Pharmaceuticals Overview
6.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.8.5 Actelion Pharmaceuticals Recent Developments
6.9 Daiichi Sankyo
6.9.1 Daiichi Sankyo Corporation Information
6.9.2 Daiichi Sankyo Overview
6.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.9.5 Daiichi Sankyo Recent Developments
6.10 Northern Therapeutics
6.10.1 Northern Therapeutics Corporation Information
6.10.2 Northern Therapeutics Overview
6.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.10.5 Northern Therapeutics Recent Developments
6.11 Aires Pharmaceuticals
6.11.1 Aires Pharmaceuticals Corporation Information
6.11.2 Aires Pharmaceuticals Overview
6.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.11.5 Aires Pharmaceuticals Recent Developments
6.12 Arena Pharmaceuticals
6.12.1 Arena Pharmaceuticals Corporation Information
6.12.2 Arena Pharmaceuticals Overview
6.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.12.5 Arena Pharmaceuticals Recent Developments
6.13 Berlin Cures
6.13.1 Berlin Cures Corporation Information
6.13.2 Berlin Cures Overview
6.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.13.5 Berlin Cures Recent Developments
6.14 Eiger BioPharmaceuticals
6.14.1 Eiger BioPharmaceuticals Corporation Information
6.14.2 Eiger BioPharmaceuticals Overview
6.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.14.5 Eiger BioPharmaceuticals Recent Developments
6.15 Reata Pharmaceuticals
6.15.1 Reata Pharmaceuticals Corporation Information
6.15.2 Reata Pharmaceuticals Overview
6.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in United States Market (2016-2021)
6.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Description
6.15.5 Reata Pharmaceuticals Recent Developments
7 United States Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Analysis
7.1 United States Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, 2016-2027
7.2 Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Pulmonary Arterial Hypertension (PAH) Drugs Supply Chain Analysis
9.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
9.2 Pulmonary Arterial Hypertension (PAH) Drugs Upstream Market
9.3 Pulmonary Arterial Hypertension (PAH) Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Pulmonary Arterial Hypertension (PAH) Drugs in United States Market
Table 2. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Companies, 2016-2021
Table 5. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies, (K Pcs), 2016-2021
Table 6. United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Price (2016-2021) & (USD/Pcs)
Table 8. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 9. List of Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Inhalation
Table 12. Major Manufacturers of Injectables
Table 13. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2016-2021
Table 17. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2022-2027
Table 18. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2016-2021
Table 22. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2022-2027
Table 23. Pfizer Corporation Information
Table 24. Pfizer Description and Major Businesses
Table 25. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 26. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 27. Pfizer Recent Developments
Table 28. Glaxosmithkline Corporation Information
Table 29. Glaxosmithkline Description and Major Businesses
Table 30. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 31. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 32. Glaxosmithkline Recent Developments
Table 33. Novartis Corporation Information
Table 34. Novartis Description and Major Businesses
Table 35. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 36. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 37. Novartis Recent Developments
Table 38. United Therapeutics Corporation Information
Table 39. United Therapeutics Description and Major Businesses
Table 40. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 41. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 42. United Therapeutics Recent Developments
Table 43. AstraZeneca Corporation Information
Table 44. AstraZeneca Description and Major Businesses
Table 45. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 46. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 47. AstraZeneca Recent Developments
Table 48. Merck Corporation Information
Table 49. Merck Description and Major Businesses
Table 50. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 51. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 52. Merck Recent Developments
Table 53. Bayer Healthcare Corporation Information
Table 54. Bayer Healthcare Description and Major Businesses
Table 55. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 56. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 57. Bayer Healthcare Recent Developments
Table 58. Actelion Pharmaceuticals Corporation Information
Table 59. Actelion Pharmaceuticals Description and Major Businesses
Table 60. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 61. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 62. Actelion Pharmaceuticals Recent Developments
Table 63. Daiichi Sankyo Corporation Information
Table 64. Daiichi Sankyo Description and Major Businesses
Table 65. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 66. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 67. Daiichi Sankyo Recent Developments
Table 68. Northern Therapeutics Corporation Information
Table 69. Northern Therapeutics Description and Major Businesses
Table 70. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 71. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 72. Northern Therapeutics Recent Developments
Table 73. Aires Pharmaceuticals Corporation Information
Table 74. Aires Pharmaceuticals Description and Major Businesses
Table 75. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 76. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 77. Aires Pharmaceuticals Recent Developments
Table 78. Arena Pharmaceuticals Corporation Information
Table 79. Arena Pharmaceuticals Description and Major Businesses
Table 80. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 81. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 82. Arena Pharmaceuticals Recent Developments
Table 83. Berlin Cures Corporation Information
Table 84. Berlin Cures Description and Major Businesses
Table 85. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 86. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 87. Berlin Cures Recent Developments
Table 88. Eiger BioPharmaceuticals Corporation Information
Table 89. Eiger BioPharmaceuticals Description and Major Businesses
Table 90. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 91. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 92. Eiger BioPharmaceuticals Recent Developments
Table 93. Reata Pharmaceuticals Corporation Information
Table 94. Reata Pharmaceuticals Description and Major Businesses
Table 95. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 96. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product
Table 97. Reata Pharmaceuticals Recent Developments
Table 98. Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs) of Key Manufacturers in United States Market, 2019-2021 (K Pcs)
Table 99. United States Pulmonary Arterial Hypertension (PAH) Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 100. Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunities & Trends in United States Market
Table 101. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers in United States Market
Table 102. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints in United States Market
Table 103. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials
Table 104. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials Suppliers in United States Market
Table 105. Typical Pulmonary Arterial Hypertension (PAH) Drugs Downstream
Table 106. Pulmonary Arterial Hypertension (PAH) Drugs Downstream Clients in United States Market
Table 107. Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
Figure 2. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type
Figure 3. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application
Figure 4. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Overview: 2020
Figure 5. United States Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Pulmonary Arterial Hypertension (PAH) Drugs Sales in United States Market: 2016-2027 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2020
Figure 9. Inhalation Product Picture
Figure 10. Injectables Product Picture
Figure 11. Oral Administration Product Picture
Figure 12. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2016-2027
Figure 13. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2016-2027
Figure 14. By Type - United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2016-2027
Figure 15. Hospitals
Figure 16. Clinics
Figure 17. Other
Figure 18. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2016-2027
Figure 19. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2016-2027
Figure 20. By Application - United States Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2016-2027
Figure 21. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 22. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Merck Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. United States Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs), 2016-2027
Figure 37. Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
Figure 38. Marketing Channels

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 103

Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market: According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to ......

Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Nifedipine market: According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......

Global Amlodipine Besylate Market Research Report 2024

Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 115

The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......

Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 112

The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......

Captopril API - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 100

The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......

Telmisartan - Global Market Insights and Sales Trends 2024

Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 107

The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......

Global Ambrisentan Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 106

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Ambrisentan Market Research Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 2680 Onwards        Pages: 132

Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......

Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028

Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 133

Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs